IKT Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Inhibikase Therapeutics Inc

Watchlist Manager

Watchlist

Price: 2.33 USD -3.32% Market Closed

Market Cap: $307.6m

	Inhibikase Therapeutics Inc NASDAQ:IKT	US
P	Proto Labs Inc F:PRZ	US
	M&T Bank Corp NYSE:MTB	US
K	Kilroy Realty Corp F:KRC	US
D	Dermapharm Holding SE XHAM:DMP	DE
H	Heidelberg Pharma AG XHAM:HPHA	DE
S	SP Group A/S F:1PU2	DK
P	Polytec Holding AG XMUN:P4N	AT
	DSV A/S F:DS81	DK
	MTR Corp Ltd F:MRI	HK
S	Springer Nature AG & Co KgaA F:SPG	DE
H	Heidelberg Pharma AG F:HPHA	DE
S	Sandvik AB OTC:SDVKY	SE
	Washington H. Soul Pattinson and Company Ltd OTC:WSOUF	AU
V	Verizon Communications Inc BMV:VZ	US

Profitability Summary

Inhibikase Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Low Operating Margin

Negative 3Y Average Operating Margin

-11 950%

Low Net Margin

Negative 3Y Average Net Margin

-11 469%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-10 304%

Negative ROE

-36%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-5 604%

Declining ROIC

-2 500% > -6 387%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.